<DOC>
	<DOCNO>NCT00776620</DOCNO>
	<brief_summary>The objective study compare relative bioavailability glimepiride 1 mg tablet ( manufacture Ranbaxy Laboratories Limited ) AMARYLÂ® 1 mg tablet ( follow single oral dose ( 1 x 1 mg tablet ) healthy , adult subject feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Glimepiride 1mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single-dose , crossover , bioequivalence study glimepiride compare glimepiride 1mg tablet Ranbaxy laboratory limit Amaryl 1mg tablet healthy , adult , human , subject feed condition . Thirty-two ( 32 ) subject recruit study subject healthy adult . Thirty-two ( 32 ) subject begin study , thirty-two ( 32 ) complete clinical portion study .</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Source Subjects : Noninstitutionalized subject consist member community large . Characterization Study Group . All subject select study least 18 year age . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history . Each female subject give serum pregnancy test part prestudy screen process . At end study , subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow : Hematology : hemoglobin , hematocrit , red blood cell count , platelet , white blood cell count ( differential ) . Clinical Chemistry : creatinine , BUN , glucose , SGOT/AST , SGPT/ALT , bilirubin , alkaline phosphatase . Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell . HIV Screen : ( prestudy ) HepatitisB , C Screen : ( prestudy ) Drugs Abuse Screen : prestudy checkin study period Subjects select normal . Electrocardiograms participate subject record initiation study file subject 's case report form . Subjects history chronic alcohol consumption I , ( past 2 year ) , drug addiction , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range may retested . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test exclude study . d. All subject urine sample assay presence drug abuse part clinical laboratory screening procedure checkin . Subjects find urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . Female subject pregnant , breastfeeding , likely become pregnant study allow participate . Female subject child bear potential must either abstain sexual intercourse use reliable barrier method ( e.g.condom , IUD ) contraception course study ( first dose last blood collection ) allow participate . Subjects use implant injected hormonal contraceptive anytime 6 month prior study dose , use oral hormonal contraceptive within 14 day dose allowed participate . All female subject screen pregnancy checkin study period . Subjects positive Inconclusive result withdraw study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence Glimepiride Tablets</keyword>
</DOC>